Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  American Journal of Obstetrics and Gynecology

• Publication date

  2009-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ajog.2008.08.030PMID 19110234
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Azacitidine

  2012cited by this paper
• Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines.

  2007cited by this paper
• Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models

  2007cited by this paper
• Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer

  2006cited by this paper
• Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer

  2005cited by this paper
• Apoptosis: mechanisms and relevance in cancer

  2005cited by this paper
• Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer

  2005cited by this paper
• DNA Methylation and Demethylation as Targets for Anticancer Therapy

  2005cited by this paper
• DNA Methylation and Epigenotypes

  2005cited by this paper
• The epigenetics of ovarian cancer drug resistance and resensitization.

  2004cited by this paper
• Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer.

  2004cited by this paper
• Anticancer therapy targeting the apoptotic pathway.

  2003cited by this paper
• Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.

  2002cited by this paper
• Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.

  2002cited by this paper
• Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines.

  2002cited by this paper
• Rel/NF-κB Transcription Factors Protect against Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Up-regulating the TRAIL Decoy Receptor DcR1*

  2001cited by this paper
• Microsatellite instability, MLH‐1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors

  2001cited by this paper
• Activity of ALRT 1550, a new retinoid, with interferon-&ggr; on ovarian cancer cell lines

  2001cited by this paper
• 5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs.

  2001cited by this paper
• Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.

  2000cited by this paper
• A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

  1999cited by this paper
• Modulation of Igf2 genomic imprinting in mice induced by 5-azacytidine, an inhibitor of DNA methylation.

  1997cited by this paper
• Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity.

  1995cited by this paper
• Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.

  1994cited by this paper
• Cancer of the ovary.

  1993cited by this paper
• Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group.

  1990cited by this paper
• Phase II study of 5-Aza-2′-deoxycytidine in advanced ovarian carcinoma

  1990cited by this paper
• Reactivation of a methylation-silenced gene in adenovirus-transformed cells by 5-azacytidine or by E1A trans activation

  1989cited by this paper
• The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas.

  1987cited by this paper
• Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells.

  1986cited by this paper
• Comparative properties of five human ovarian adenocarcinoma cell lines.

  1985cited by this paper

• Effectiveness of azacytidine for poly ADP-ribose polymerase inhibitor-induced myelodysplastic syndrome in ovarian cancer patient: a twofold triumph.

  2026cites this paper
• A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML

  2025cites this paper
• The Effects of Natural Epigenetic Therapies in 3D Ovarian Cancer and Patient-Derived Tumor Explants: New Avenues in Regulating the Cancer Secretome

  2023cites this paper
• Effect of Zebularine on Apoptotic Pathways in Hepatocellular Carcinoma Cell Lines

  2023cites this paper
• Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.

  2022cites this paper
• Driving Immune Responses in the Ovarian Tumor Microenvironment

  2021cites this paper
• Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer

  2021cites this paper
• Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer

  2021cites this paper
• Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer

  2021cites this paper
• Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines

  2021cites this paper
• Prediction of biomarker signatures and therapeutic agents from blood sample against Pancreatic Ductal Adenocarcinoma (PDAC): A network-based study

  2020cites this paper
• Targeting DNA Repair in Ovarian Cancer Treatment Resistance.

  2020cites this paper
• Expression profiling of DNA methyl transferase I (DNMT1) and efficacy of a DNA-hypomethylating agent (decitabine) in combination with chemotherapy in osteosarcoma

  2020cites this paper
• Identification of Blood-based Non-invasive Biomarkers and Therapeutic Agents against Pancreatic Ductal Adenocarcinoma (PDAC): A Network-based Study

  2020cites this paper
• Use of Epigenetic Therapy Shortens Duration of Standard Chemotherapy for Ovarian Cancer with Minimal Toxicity to Normal Tissue

  2020cites this paper
• Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer

  2019cites this paper
• Understanding and Targeting Apoptotic Pathways in Ovarian Cancer

  2019influential citation
• DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies.

  2019cites this paper
• Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors

  2018cites this paper
• Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

  2018cites this paper
• Epigenetic loss of heparan sulfate 3‐O‐sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis

  2018cites this paper
• Epigenetic Modulations in Ovarian Cancer

  2018cites this paper
• Everolimus following 5-aza-2-deoxycytidine is a promising therapy in paclitaxel-resistant clear cell carcinoma of the ovary.

  2018cites this paper
• The role of human CBX proteins in human benign and malignant hematopoiesis

  2018cites this paper
• Azacytidine-induced Chemosensitivity to Doxorubicin in Human Breast Cancer MCF7 Cells.

  2017cites this paper
• Epigenetics in ovarian cancer.

  2017cites this paper
• Epigenetic Targeting of Platinum Resistant Testicular Cancer.

  2016cites this paper
• Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors

  2016cites this paper
• Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer.

  2016cites this paper
• Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response

  2016cites this paper
• Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications

  2016cites this paper
• Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy

  2015cites this paper
• Voltammetric studies of topotecan transfer across liquid/liquid interfaces and sensing applications.

  2015cites this paper
• Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway

  2015cites this paper
• MTRR silencing inhibits growth and cisplatin resistance of ovarian carcinoma via inducing apoptosis and reducing autophagy.

  2015cites this paper
• Gene methylation of human ovarian carcinoma stromal progenitor cells promotes tumorigenesis

  2015cites this paper
• Therapeutic implications for ovarian cancer emerging from the Tumor Cancer Genome Atlas

  2015cites this paper
• The regulations of miR-30c-3-3p and its antitumor mechanism in ovarian cancer

  2015cites this paper
• Combating the Epigenome: Elucidation of Mechanisms Underlying Chemoresistance and Enhancing Tumor Immunogenicity

  2015cites this paper
• Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment

  2014cites this paper
• Molecular Epigenetics in the Management of Ovarian Cancer: Are We Investigating a Rational Clinical Promise?

  2014cites this paper
• Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors

  2014cites this paper
• The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer

  2014cites this paper
• Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients.

  2014cites this paper
• Analyse globale des altérations abberantes de la méthylation de l'ADN dans le cancer de l'ovaire

  2013cites this paper
• Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies

  2013cites this paper
• Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3.

  2013cites this paper
• Epigenetic resensitization to platinum in ovarian cancer.

  2012cites this paper
• Epigenetic silencing of DKK 2 and Wnt signal pathway components in human ovarian carcinoma

  2012cites this paper
• Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma.

  2012cites this paper
• Epigenetics in ovarian cancer.

  2012cites this paper
• Targeting the epigenome in ovarian cancer.

  2012cites this paper
• Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy

  2011cites this paper
• Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer

  2011cites this paper
• Molecular Targeted Therapy in Ovarian Cancer

  2011cites this paper
• Epigenetics of ovarian cancer: from the lab to the clinic.

  2010cites this paper
• A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer

  2010cites this paper
• Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis.

  2010cites this paper
• Overcoming TRAIL resistance in ovarian carcinoma.

  2010cites this paper
• Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.

  2010cites this paper
• Minireview: epigenetic changes in ovarian cancer.

  2009cites this paper
• Development of novel agents for ovarian cancer

  2009cites this paper
• 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats.

  2009cites this paper